AO 2025-0030 in Force: The Four Pillars of the Post-Marketing Alert System (PMAS)

1. Key takeaways

Department of Health Administrative Order No. 2025-0030 (AO No. 2025-0030) took effect on 6 May 2026. It formally adopts the Post-Marketing Alert System (PMAS) requirements of Annex 5 of the ASEAN Medical Device Directive (AMDD) and establishes a mandatory post-market surveillance framework. The framework rests on four pillars: importation and distribution record keeping (traceability), complaint handling and documentation, adverse event reporting, and field safety corrective action (FSCA). A 1-year transition period applies, running until May 2027.

• Four obligations become mandatory at the same moment. Record keeping, complaint handling, adverse event reporting and FSCA were previously dispersed across separate circulars; they are now a single framework with a single compliance date.
• Scope covers all medical devices, including IVD, and binds manufacturers, marketing authorisation holders (MAH), importers, distributors and traders.
• The FDA assessment clock is now statutory. Preliminary assessment must be completed within 7 working days of receiving a post-market alert, and full risk assessment within 20 working days.
• The transition period ends in May 2027. It is an implementation window for building systems, not a grace period for deferring them.
• Enforcement sits under RA No. 3720 as amended by RA No. 9711, so post-market failures connect directly to the wider penalties regime rather than to a stand-alone administrative circular.

2. Legal basis

AO No. 2025-0030 domesticates Annex 5 of the AMDD into Philippine practice. The table below sets out the elements that determine how the framework operates in day-to-day compliance work.

3. Expert insights

Insight 1: this is the watershed at which Philippine post-market regulation moves from advocacy to compulsion.

Before AO No. 2025-0030, post-market requirements were scattered across individual circulars and there was no unified framework. The Administrative Order localises Annex 5 of the AMDD in full, so that record keeping, complaint handling, adverse event reporting and FSCA become mandatory obligations at the same time, with a defined 1-year transition. For companies, the practical meaning is that post-market compliance shifts from something done when convenient to something whose absence is itself a violation. The change is structural rather than incremental: the obligations no longer depend on which circular a particular product happened to fall under.

Insight 2: the FDA assessment timelines have been given legal force, and this constrains companies as much as it constrains the regulator.

Under the Ease of Doing Business Act (RA No. 11032), AO No. 2025-0030 imposes timelines on the FDA itself: preliminary assessment within 7 working days and full risk assessment within 20 working days. The design has a two-way meaning — if the FDA must respond within the clock, the company report must be in place before the clock starts. Regulatory speed is transmitted back to the regulated party as a requirement for faster internal response. A company that needs three weeks to decide whether an event is reportable cannot operate inside a seven-day preliminary assessment cycle, because by the time its internal conclusion is reached the regulator is already expected to have completed its own first pass.

Insight 3: IVD is explicitly included, and the framework introduces the concept of indirect harm.

The scope of AO No. 2025-0030 expressly covers IVD. For IVD, the most consequential rule is that indirect harm arising from an erroneous test reading that leads to delayed or incorrect treatment is a clearly reportable adverse event. There is no direct counterpart to this concept in the general device framework, and it is precisely where IVD companies must build a separate assessment standard. A reader that returns a wrong result without any physical failure of the instrument is, under this rule, a reportable event if treatment is delayed or wrong as a consequence.

Insight 4: the transition period is a window for action, not a period of waiting.

The transition period is 1 year, counted from 6 May 2026. GRZAN’s assessment is that companies which complete system building inside the transition period will be in a stronger position in later regulatory inspections, while companies that treat the transition as a buffer will see problems surface together in 2027. Specific actions are set out in the recommendations below.

4. Practical recommendations

• Run a gap analysis against the four pillars. Assess record keeping, complaint handling, adverse event reporting and FSCA procedures item by item, and mark each as existing, partial or absent. The output should be a single matrix with an owner and a target date for every gap.
• Turn each SOP into a controlled document. One SOP per pillar, each naming the responsible function and the response deadline it enforces. Undocumented practice is not a system under this framework.
• Define the starting point of the clock explicitly. Write down the rule used to determine the moment of awareness, including awareness held by distributors, and apply it consistently across affiliates and channel partners.
• Establish a 14-day handover mechanism with distributors. Put the obligation into the distribution agreement and attach consequences for breach, so that the contractual layer supports the regulatory one.
• Run one simulation inside the transition period. Walk a hypothetical event through the reporting and FSCA process end to end, including the regulator-facing documents, and record where the process stalls.

5. Verification checklist

• □ AO No. 2025-0030 effective date confirmed as 6 May 2026
• □ Transition period end confirmed as May 2027
• □ Scope confirmed to include IVD
• □ Record-keeping SOP established and operating
• □ Complaint-handling SOP established and operating
• □ Adverse event reporting deadlines mapped (48 hours / 10 days / 30 days)
• □ FSCA procedure established and tested in a simulation
• □ FDA assessment timelines understood by the regulatory function (7 working days / 20 working days)

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including the Philippines. Our team prepares CMDN/CMDR dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the FDA Philippines, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com